Molecular screening testing for colorectal cancer

Clinical Cancer Research

Volumn 12, Issue 17, 2006, Pages 5014-5017

  Levin, Bernard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CYTOLOGY; DNA DETERMINATION; FECES ANALYSIS; GENE MUTATION; HUMAN; INTESTINE CELL; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW;

COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; GENETIC SCREENING; HUMANS; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33748997086     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0578     Document Type: Review

References (51)

1. Globocan. Cancer incidence mortality & prevalence worldwide 2000 estimates; 2000.
2. American Cancer Society. Cancer facts & figures; 2006.
3. Colorectal cancer test used among persons aged > or = 50 years. United States, 2001. Morb Moral Wkly Rep 2003;52:193-96.
4. Young GP, St John DJB, Winawer SJ, et al. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol 2002;97:2499-507.
5. Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299-305.
6. Saitoh O, Matsumoto H, Sugimori K, et al. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin and α-a-antitrypsin in patients with colorectal diseases. Digestion 1995;56:67-75.
7. Bandaletova T, Bailey N, Bringham SA, Loktionov A. Isolation of exfoliated colonocytes from human stool as a new technique for colonic cytology. APMIS 2002;110:239-46.
8. Loktionov A, O'Neill IK, Silvester KR, et al. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel non-invasive screening test for colorectal cancer. Clin Cancer Res 1998;4:337-42.
9. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-9.
10. Sidransky D. Emerging molecular markers of cancers. Nat Rev Cancer 2002;2:210-9.
11. Davis RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005;5:199-209.
12. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
13. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
14. Diehl F, Li M, Dressman D, et al. Detection of quantifications of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
15. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004;23:11-27.
16. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
17. Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;48:185-7.
18. Whitney D, Skoletsky J, Moore K, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004;6:386-95.
19. Boynton KA, Summerhayes IC, Ahlquist DE, Shuber AP. DNA integrity as a potential marker for stool based detection of colorectal cancer. Clin Chem 2003;49:1058-65.
20. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
21. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005;14:183-91.
22. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84.
23. Mller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.
24. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras sequences in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
25. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
26. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
27. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-4.
28. Eguchi S, Kohara N, Komuta K, et al. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;77:1707-10.
29. Snover DC, Jass JR, Fenoglio-Preiser C, et al. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 2005;124:380-91.
30. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
31. Brenner D, Rennert G. Fecal DNA biomarkers for detection of colorectal neoplasia: attractive but is it feasible? J Natl Cancer Inst 2005;97:1107-9.
32. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97:1124-32.
33. Dong S, Traverso G, Johnson C, Geng L. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.
34. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
35. Itzkowitz S, Jandorf L, Brand R, et al. Improved performance of a noninvasive fecal DNA (fDNA) test to screen for colorectal cancer [abstract]. Gatroenterology 2006;130:51862.
36. Young GP, Rozen P. Fecal immunochemical tests for hemoglobin (FITs): a paradigm shift in non-invasive fecal screening tests for colorectal cancer. World Gastroenterol News 2006;2.
37. Colin A, Smith G, Lorey FA, Wolf CR, Steele RJC. Mutations in colorectal carcinoma. Gut 2005;54:1283-6.
38. Slebos RC, Baas IO, Clement M, et al. Clinical and pathological associations wit p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996;74:165-71
39. Ratto C, Flamini G, Sofo L, et al. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 1996;39:1238-44.
40. Villa E, Dugani A, Rebecchi AM, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996;110:1346-53.
41. Puig P, Urgell E, Capella G, et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 2000;85:73-7.
42. Wan J, Zhang ZQ, You WD, et al. Detection of Kras gene mutation in fecal samples from elderly large intestinal cancer patients and its diagnostic significance. World J Gastroenterol 2004;10:743-6.
43. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool (feasibility of a multitarget assay panel). Gastroenterology 2000;119:1219-27.
44. Tagore K, Lawson M, Yucaitis J, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003;3:47-53.
45. Syngal S, Chung D, Willet C, Schoetz D. Stool DNA analysis for the detection and follow-up of colorectal cancer (CRC) and advanced adenomas (AA) (sensitivity in a prospective series). Gastroenterology 2002;97:332.
46. Syngal S, Chung D, Willet C, et al. Stool DNA analysis for the detection and follow-up of colorectal cancer (CRC) in advanced adenomas (AA) (sensitivity in a prospective series). Am J Gastroenterol 2002;97:S109.
47. Brand R, Shuber A, Laken S, Young C. Reliability of stool DNA mutation specific assay for colorectal cancer. Gastroenterology 2002;122:479.
48. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003;1:377-83.
49. Ahlquist DA, Sargent DJ, Levin TR, et al. Stool DNA screening for colorectal cancer: prospective multitarget comparison with hemoccult [abstract 424]. Gastroenterology 2005;128:63.
50. Rengucci C, Maiolo P, Saragoni L, Zoli W. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001;7:590-3.
51. Koshiji M, Yonekura Y, Saito T, Yoshioka K. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol 2002;80:34-40.